Kornimate/medical-research-clean huggingface dataset:
medical nutrition therapy or standard care in treating patients with lung cancer, pancreatic cancer, or stage iii or stage iv prostate cancer

Conditions: Lung Cancer; Malnutrition; Pancreatic Cancer; Prostate Cancer; Weight Changes

Summary: this is a two-part study. part i is an observational study. part ii is a randomized clinical trial to see how well medical nutrition therapy works compared with standard care in treating patients with lung cancer, pancreatic cancer, or stage iii or stage iv prostate cancer.

in part ii of the study, patients are stratified according to tumor type (pancreatic vs lung vs prostate). patients are then randomized to 1 of 2 arms. * arm i (medical nutrition therapy): intervention with a registered dietitian or nutrition professional. mnt is a cyclical process which includes nutrition assessment, intervention, follow-up, and reassessment. patients will receive a total of three (3) visits with the dietitian over a six-week period with follow-up during weeks 2-3 and weeks 6-9 based on their treatment schedule. * arm ii (standard care): standard nutritional care includes the national cancer institute's booklet "eating hints for cancer patients: before, during \& after treatment". in both arms, patients' weight, fat free mass, and patient generated subjective global assessment score (pg-sga) score will be assessed before, during, and after the intervention. the pg-sga includes a patient report of symptoms and a healthcare professional assessment of medical, metabolic, and physical parameters.

Eligibility criteria:
disease characteristics: * diagnosed with one of the following: * pancreatic cancer * lung cancer * stage iii or iv prostate cancer * undergoing treatment at the cancer institute of new jersey * are undergoing chemotherapy (part 2 only) * has lost ≥ 5% of their usual body weight in the previous 6 months (part 2 only) patient characteristics: * life expectancy \> 60 days * must speak and read english * accessible in person or by phone for completing questionnaires * not pregnant or nursing prior concurrent therapy: * see disease characteristics

Keywords: malnutrition non-small cell lung cancer small cell lung cancer stage iii prostate cancer stage iv prostate cancer pancreatic cancer weight changes
methodology issues in a tailored light treatment for persons with dementia

Conditions: Sleep Disturbances; Depression

Summary: tailored light treatment will increase sleep efficiency, reduce depression and reduce agitation scores in those with alzheimer's disease and related dementia

in a within subjects, randomized placebo control study, a tailored light treatment will be used for short-term (4 weeks). outcome measures include sleep measures (actigraphy), and questionnaires probing behavior and mood in those who have been diagnosed with alzheimer's disease and related dementia. after a 4-week washout period, a placebo control inactive light will be used for another 4 weeks.

Eligibility criteria:
inclusion criteria: * mild to moderate alzheimer's disease and related dementia (adrd) exclusion criteria: * major organ failure, * major illness, * history of head injury, * hypertension or diabetes, * use psychotropic (sleep aid) medicine, obstructing cataracts, macular degeneration, and blindness

Keywords: light treatment circadian rhythms sleep agitation depression
a study of the continuous glucose monitoring system for home use in patients with diabetes

Conditions: Diabetes

Summary: subjects in the upper arm group will have a sensor of the cgm system inserted on each arm (left and right upper arm). subjects in the abdomen group will have 2 sensors inserted, one on each side of the abdomen (left and right abdomen) the sensors will be placed for 29 days. after sensor insertion, the cgm system should be calibrated with capillary blood glucose readings from a self-monitoring blood glucose meter。


Eligibility criteria:
inclusion criteria: 1. type 1 or 2 diabetes mellitus 2. male or female age ≥ 18 years old and ≤ 70 years old 3. willingness to adopt measures to prevent water coming into contact with the device sensor (e.g. abstain from swimming, sauna, avoid hitting the sensor with direct jets of water) 4. ability to communicate with the investigators, able to operate medical device after training and comply with the testing procedures outlined in this protocol (including, but not limited to, willing to wear the continuous glucose monitor and testing capillary blood glucose) 5. subjects who show understanding of the study procedures and willing to sign a written informed consent form. exclusion criteria: 1. hospitalization due to diabetic ketoacidosis or severe hypoglycemia, within 3 months prior to screening 2. hba1c \>13% or urine ketone 3+ 3. use of pacemaker 4. body mass index (bmi) ≤18.0kg/m2 5. extensive skin changes/diseases that preclude wearing the required number of devices on normal skin at the proposed application sites, i.e. upper arm or abdomen (e.g., extensive psoriasis, recent burns or severe sunburn, extensive eczema, extensive scarring, extensive tattoos, dermatitis herpetiformis) 6. any psychiatric disease such as depression or anxiety 7. any severe hepatic, renal, cardiac, cerebral, respiratory or neurological diseases (e.g. serum alt, ast, creatinine level ≥3 times the upper limit of normal) 8. has a mri scan, ct scan or other procedure requiring the subject be under strong magnetic or electromagnetic environment, scheduled during the proposed study participation 9. blood loss \>400ml in the past 3 months (including blood donation) 10. have a known allergy to medical-grade adhesives, or known hypersensitivity to any of the products used in the study 11. difficulty in sampling venous blood or cannot tolerate venipuncture 12. participated in other investigational studies in the past 3 months 13. currently pregnant or lactating women, or positive pregnancy test 14. any condition that, in the opinion of the investigator, renders the subject not suitable for the study.
adherence to antihypertensive therapy--data analyses

Conditions: Cardiovascular Diseases; Hypertension

Summary: to assess factors that may influence adherence to antihypertensive drug therapy.

background: high blood pressure continues to be a highly prevalent condition affecting about 20 percent of the u.s. population. untreated, it may lead to coronary heart disease, stroke, kidney failure, and other complications. medication is a major means of controlling hypertension and averting these debilitating consequences. treatment with drugs, however, is undermined by suboptimal adherence to therapy. forgetting to take medications is the most commonly elicited reason for lapses in medication use; but side effects, health beliefs, lack of knowledge of disease and treatment instructions, and financial barriers may also interfere. determining those factors that (1) are predictably associated with fluctuations in adherence (such as day of the week, holidays, medication appointments); (2) ameliorate the impact of nonadherence, such as pharmacologic properties of drugs that protect patients during adherence lapses; and (3) correlate with the accuracy of adherence reporting by patients will assist in anticipating and addressing adherence obstacles and serve as the objectives of the study. design narrative: the study used data collected from electronic adherence monitors, questionnaires, and computerized medical records that contained blood pressure readings during a prior investigation of antihypertensive adherence. this earlier investigation, conducted from 1994 to 1997, involved 286 members of harvard pilgrim health care who were on single drug therapy for mild to moderate hypertension. objective 1 evaluated the impact of temporal factors such as weekend versus weekday, holidays, seasons, and impending medical appointments on adherence by analyzing their effects on the daily rate of dosing recorded by electronic medication monitors. time trend models were used for this purpose. objective 2 assessed the impact of pharmacologic duration of action on the level of antihypertensive adherence required to maintain a goal blood pressure of \<140/90 mmhg. this involved determining if the relationship between adherence and blood pressure was modified by the duration of drug effect. objective 3 concerning correlates of accuracy of reported adherence was approached by verifying reported adherence against electronically measured adherence. predictors and correlates of accurately reported adherence such as patient age, gender, race/ethnicity, education, socioeconomic status, health beliefs, and measures of health status were then identified by cross tabulating and statistical modeling accurate reporting against these factors. the study completion date listed in this record was obtained from the "end date" entered in the protocol registration and results system (prs) record.

Eligibility criteria:
no eligibility criteria
weekly versus three-week chemoradiation in patients with advanced cervical cancer

Conditions: Cervical Cancers

Summary: three weekly cisplatin based chemoradiation is to be compared the compliance, toxicity, and response rates with the weekly cisplatin based chemoradiation in the treatment of locoregionally advanced cervical cancers.

this study is to compare the compliance, toxicity, response and survival rate between concurrent chemoradiation with weekly cisplatin 40mg/m2 and three-week cisplatin 75mg/m2 in patients with advanced cervical cancer. patients with primary untreated invasive squamous cell carcinoma, adenosquamous carcinoma or adenocarcinoma of the cervix from stage iib to iva were enrolled. patients with histologically proven locoregionally advanced cervical cancer will be randomized into two treatment arm; arm i, concurrent chemoradiation with weekly cisplatin 40mg/m2 for six times; arm ii, concurrent chemoradiation with three-week cisplatin 75mg/m2 for three times. the compliance and toxicity during the chemoradiation is the primary endpoint. response rate and the overall survival will be analyzed as secondary endpoints.

Eligibility criteria:
inclusion criteria: * histologically proven cervical cancer * squamous, adenosquamous, adeno carcinoma cell type * international federation of gynecologic oncology (figo) stage iib - iva * gynecologic oncology group (gog) performance status 0 - 2 exclusion criteria: * previous history of chemotherapy or radiation * history of other cancer * hypersensitivity to platinum agents * pregnancy * serious medical disease

Keywords: cervical neoplasm chemoradiation compliance toxicity
restrictive versus standard fluid regime in elective minilaparotomy abdominal aortic aneurysm repair

Conditions: Abdominal Aortic Aneurysm > 5.5 cm Effect of a Restricted Intravenous Fluid Regime on Complications and Hospital Stay After the Minilaparotomy AAA Repair.

Summary: elective minilaparatomy abdominal aortic aneurysm (aaa) repair is associated with a significant number of complications involving respiratory, cardiovascular, gastrointestinal and central nervous system, and mortality ranging up to 5%. in our study, we tested the hypothesis that intraoperative and postoperative intravenous restrictive fluid regime reduces postoperative morbidity and mortality and improves the outcome of the treatment of minilaparotomy aaa repair.

we investigate effects of a restricted fluid regime versus standard regimen on complications and hospital stay after minilaparatomy aortic aneurysm repair.

Eligibility criteria:
inclusion criteria: * aaa more than 5,5 cm in diameter tube graft exclusion criteria: * emargency comorbidity maligancy

Keywords: minilaparotomy aaa fluid regime
effects of dry needling on sternocleidomastoid muscle for pain and disability in migraine

Conditions: Migraine

Summary: to determine the effects, sequel of dry needling in migraine by resolving mtrps in sternocleidomastoid muscle. to determine the possession of dry needling technique to mitigate the frequency, intensity and duration of headache. to determine the effectiveness of dry needling in the disability hindrance in migraine patients.

this is a randomized control study of 60 volunteers with migraine induced by myofacial triggers in sternocleidomastoid muscle. the migraine will be diagnosed by the neurologist and for the evaluation of trigger points and muscle thickness ultrasound will be done. after the diagnostic procedure and complete history evaluation from the selected population 30 subjects will be subjected to dry needling group and 30 others will be kept in the placebo group. all the participants will receive six sessions at the myofascial trigger point area there should be the gap of at least 48 hours between two sessions. as for the assessment details, such as the frequency, intensity and duration of the headaches; the consumption of drugs; the thickness of scm muscles; the pain pressure threshold and the cervical range motions will be recorded before, immediately following the response, and at the 1-month follow-up

Eligibility criteria:
inclusion criteria: * submitted with a headache diagnosis by a neurologist. * presence of active trigger points in the sternocleidomastoid muscle reproducing the symptoms of migraine. * active trigger points will be identified if "there is muscle sensitivity that has been activated by pressure and reproduces the patient's referred pain and headache." * a jump sign the characteristic behavioral response to compression on a trigger point, will be produced. exclusion criteria: * background of neck trauma * cervical radiculopathy * history of head/shoulder surgery * diagnosis of other unusual headaches/migraines * phobia of pricking * pregnancy

Keywords: dry needling sternocleidomastoid muscle pain disability randomized control trial migraine
intra-articular viscosupplement application in knee osteoarthritis

Conditions: Knee Osteoarthritis

Summary: knee osteoarthritis (oa) is one of the common diseases which causes pain and disability with increasing age. in developed countries, it is said to be one of the ten diseases which decreases functionality most.

knee osteoarthritis (oa) is one of the common diseases which causes pain and disability with increasing age. in developed countries, it is said to be one of the ten diseases which decreases functionality most. with a prevalence between 22% - 39%, 7% of which are patients who are over 65 years old, and when examined world-wide, it is stated that knee oa is seen 18% of women and 9,6% of men. knee oa is characterized by pain, and; functional loss and progressive mobility where motions are required a physical activity of lower extremity. the disease causes 80% of restriction of motions and 25% of restriction of daily life activities. additionally, along with the loss of proprioception, it can be seen defects of static and dynamic postural stability and the loss of balance. the factors of disease cause reduced muscle strength, defects of functionality of muscles and reduced workout capacity. according to the radiographic classification of kellgren and lawrence, quadriceps muscle weakness is frequently seen without atrophy and pain in early phases of knee oa of which degree is 0 or 1. if the symptoms are accompanied by a knee pain, the weakness of muscles will show an increase more and cause dysfunction and progression of disease. an increase of force in the muscles of quadriceps and hamstring plays a positive role for stability and mobility of joints and pain tolerance. in the literature, studies with intra-articular ha injection in the treatment of knee oa are frequently seen, but the number of studies about the co-injection of ha, cs and ga is scarcely any. at the same time, studies investigating the effect of intra-articular viscosupplementation injection on isokinetic muscle strength was not observed. therefore, the investigators aimed at investigating the effects of ha, cs and ga injection on isokinetic quadriceps and hamstring muscle strengths in our study.

Eligibility criteria:
inclusion criteria: * being between 40-65 years of age, * being diagnosed with stage 3 and 4 knee oa according to the kellgren-lawrence classification exclusion criteria: * any lower extremity deformity (knee flexion contracture, knee hyperextension, varus and valgus deformities), * septic arthritis, rheumatoid arthritis, * major dysplasia, * congenital anomalies, acromegaly, primary osteochondromatosis, * ehler-danlos syndrome, * neuropathic arthropathy, * hyperparathyroidism, hypothyroidism, * diabetes mellitus, * active synovitis, * severe knee traumas, * previous surgery and in the last year, * knee arthroscopy, injections and fracture history and pregnancy
safety and tolerability of low dose primaquine

Conditions: Malaria, Falciparum; G6PD Deficiency

Summary: in cambodia, falciparum is becoming more difficult to treat because drugs are becoming less effective. the investigators can help to try to prevent the spread of this resistant malaria by adding a drug that will make it more difficult for the mosquito to drink up the malaria in people's blood. if the mosquito cannot drink up the malaria, then the malaria cannot develop in the mosquito so it will not be able to inject malaria back into people when it bites. the drug the investigators will use is called primaquine. primaquine commonly causes the red cells in the blood to break apart if they are weak. red cells need enzymes to work properly and weak red cells have low amounts of an enzyme called glucose 6 phosphate dehydrogenase (g6pd). the investigators want to know if treating malaria with primaquine will be safe for the red cells. to do this study, the investigators need to know if a subject has low g6pd or not.


Eligibility criteria:
inclusion criteria: * age ≥ 1 year * presentation with a confirmed fever (≥ 38⁰c axilla or ≥ 37.5⁰c aural) or history of fever in previous 48 hours +/- other clinical features of uncomplicated malaria * plasmodium falciparum monoinfection ≥ 1 asexual form / 500 white blood cells * informed consent (written/verbal) provided by patient or relative/legal guardian * signed assent form for children aged 12 to \< 18 years exclusion criteria: * clinical signs of severe malaria or danger signs * pregnant or breast feeding * unable or unwilling to take a pregnancy test (for women of child-bearing age) * women intending to become pregnant in the next 3 months * allergic to primaquine or dha pp * patients taking drugs known to cause acute intravascular haemolytic anaemia (aiha) in g6pd deficiency e.g. dapsone, nalidixic acid * patients on treatment for a significant illness e.g. hiv, tuberculosis (tb) treatment, steroids * on drugs that could interfere with anti-malarial pharmacokinetics like antiretrovirals, cimetidine, ketoconazole, antiepileptic drugs, rifampicin

Keywords: malaria, falciparum g6pd deficiency primaquine asia
the effect of different support surface applications

Conditions: Pressure Incidence Prevention; Pain

Summary: this study was designed as a randomized controlled experimental study to compare the effects of two support surfaces-gel pads (used in routine practice) and microbead-filled pads-placed under the shoulders in the steep trendelenburg position during robotic surgery, on the development of pressure injuries and pain.

safe and procedure-specific patient positioning is a critical component of successful surgical outcomes. in robotic surgeries, particularly those involving the lower pelvic region, the steep trendelenburg position is frequently used to optimize surgical exposure. however, as the angle of the trendelenburg position increases and the patient remains in this posture for a prolonged period, the risk of adverse events such as nerve injuries, pressure injuries, and deep tissue ischemia also increases. unlike traditional surgeries where repositioning the patient may be possible during the procedure, robotic surgeries do not allow for intraoperative repositioning due to the fixed docking of robotic arms. consequently, safe and effective positioning strategies are essential to prevent patient movement and minimize the risk of skin and soft tissue damage. the current systems used for managing patients in the steep trendelenburg position are suboptimal. there is limited evidence in the literature regarding the incidence and prevention of pressure injuries associated with this specific position during robotic surgery. prolonged immobility in this posture increases friction and pressure at contact surfaces, which can lead to pressure-related injuries. the use of appropriate support surfaces is therefore vital to reduce the risk of such injuries. this study aims to address this gap by evaluating and comparing different support surfaces placed under the shoulders during robotic surgery in the steep trendelenburg position, with a focus on their effects on pressure injury development and postoperative pain. hypotheses of the study h1: the use of microbead-filled support surfaces under the shoulders is superior to gel support surfaces in preventing pressure injuries and pain. h2: the use of gel support surfaces under the shoulders is superior to microbead-filled support surfaces in preventing pressure injuries and pain.

Eligibility criteria:
inclusion criteria: * patients scheduled to undergo robotic surgery in the lower pelvic region in the steep trendelenburg position * patients aged 18 years and older exclusion criteria: * patients with existing pressure injuries * patients with communication barriers * patients with skin anomalies that interfere with skin assessment * patients requiring conversion to open surgery during the procedure * patients whose position is changed during surgery

Keywords: pressure injury robotic surgery deep trendelenburg position pain
conservative treatment and ultrasound guided injection for treatment meralgia paresthetica

Conditions: Meralgia Paresthetica

Summary: meralgia paresthetica (mp) is an entrapment mononeuropathy of the lateral femoral cutaneous nerve (lfcn), where conservative treatment options are not always sufficient. the aim of this study was to evaluate the efficacy of ultrasound (us) guided lateral femoral cutaneous nerve injection in the management of meralgia paresthetica by comparing with transcutaneous electrical nerve stimulation (tens) therapy and sham transcutaneous electrical nerve stimulation therapy.

in this prospective, randomized, sham-controlled study, fifty four patients (23 female and 31 male, the mean age 53.61±11.99 years) with lateral femoral cutaneous nerve compression with clinical and electrophysiological findings were enrolled. patients were randomly assigned to three groups: 1) ultrasound-guided injection group, 2) tens group, 3) sham tens group. the blockage of the lateral femoral cutaneous nerve was performed for therapeutic meralgia paresthetica management in group 1. ten sessions of conventional tens were administered to each patient 5 days a week for 2 weeks, for 20 minutes per daily session in group 2, and sham tens was applied to group 3 with the same protocol. visual analog scale (vas), paindetect questionnaire (pd-q), semmes weinstein monofilament test (swmt), pittsburgh sleep quality index (psqi) and health-related quality of life (sf 36), at onset (t1), 15 days after treatment (t2) and 1 month after treatment (t3) were used for evaluation.

Eligibility criteria:
inclusion criteria * patients diagnosed with lfcn entrapment confirmed by clinical and electrophysiological findings exclusion criteria * secondary entrapment neuropathy * malignancy * pregnancy * infection in the inguinal region or dermatitis * lumbar radiculopathy * cardiac pacemakers * polyneuropathy

Keywords: meralgia paresthetica ultrasound-guided injection transcutaneous electrical nerve stimulation